I thank the gentleman for his participation. Being as he's from Texas, I also feel compelled to add that that 0.1 percent growth, you subtract out the jobs created in Texas this year--somewhere between 200,000 and 300,000--we're in a…

If the gentleman would yield for a further question. Then where do those patients go for their care? You just said it, but I would love for you to repeat it.

Inaction is not an option on this issue. However, we must do so in a way that encourages the development of innovative technologies.

I do think that ONC has a unique perspective on these HIT issues, and along with input from the FDA and from stakeholders that Congress can find a path forward on what a framework would look like.

I do hope that sets a new standard for the Administration in replying to letters from this committee.

I think that is one of the reasons these committee hearings have been so important.

The emergence of mobile medical technology does hold great promise not only for lowering the care cost, but most importantly, for improving health outcomes.

The FDA always looks to whether things are safe and effective, well, with the exception of tobacco.

I am grateful to the chairman for holding this hearing, grateful to our panel for presenting to us today.

From the newest means to detect and diagnose conditions, to the cures and diseases that once were thought untreatable, innovation has led the way to bettering the lives of patients.

I thank the gentleman for yielding and certainly thank him for leading this rule on the floor this afternoon. This is an important vote we're going to have today. The rule that will bring various budgets to the floor is a very fair…